Q3 ’23 Earnings Call Safe Harbor Statement Thispresentationcontainsforward-lookingstatementsthatarebasedonthecurrentexpectationsandbeliefsofAmgen. Allstatements,otherthanstatementsofhistoricalfact,arestatementsthatcouldbedeemedforward-looking statements,includinganystatementsontheoutcome,benefitsandsynergiesofcollaborations,orpotentialcollaborations,withanyothercompany(includingBeiGene,Ltd.orKyowaKirinCo.,Ltd.),theperformanceofOtezla®(apremilast) (includinganticipatedOtezlasalesgrowthandthetimingofnon-GAAPE ...

Financial Performance - Total revenues increased by 4% year-over-year to $6.9 billion, with non-GAAP earnings per share rising by 6% to $4.96 [38][39] - Volume growth was 11% globally, marking the fourth consecutive quarter of double-digit volume growth [6][10] - Non-GAAP operating expenses increased by 4% year-over-year, with a non-GAAP operating margin of 52% [38][39] Business Line Performance - General medicine revenue grew by 21% year-over-year, driven by a 20% volume increase, with Repatha sales up 31% [11][12] - Prolia sales increased by 14% year-over-year, while EVENITY achieved record sales of $307 million, reflecting 48% volume growth [13][14] - Otezla sales declined by 10% year-over-year, impacted by lower net selling prices and inventory levels [14][15] - Hematology-oncology products saw a 15% volume growth, with BLINCYTO sales growing by 55% to a record $220 million [18][19] Market Performance - U.S. volume growth was 11%, while Asia-Pacific was the fastest-growing region with 27% volume growth [10][11] - The rare disease business, bolstered by the Horizon acquisition, generated $945 million in sales, with Tepezza and KRYSTEXXA showing strong growth [22][27] Company Strategy and Industry Competition - The acquisition of Horizon Therapeutics is expected to enhance Amgen's rare disease portfolio and overall growth strategy [4][5] - Amgen aims to leverage its global presence to expand the reach of its rare disease medicines, which currently have significant potential in the U.S. market [5][22] - The company is focused on innovation and expanding its pipeline, with several first-in-class oncology assets progressing through clinical trials [7][30] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver attractive sales and earnings growth through the end of the decade [9][10] - The integration of Horizon's capabilities is expected to accelerate growth in the rare disease segment [22][29] - Management highlighted the importance of investments in R&D and digitalization to drive future growth [41][42] Other Important Information - The company raised its 2023 revenue guidance to $28.0 billion to $28.4 billion, reflecting the inclusion of Horizon's results starting October 6, 2023 [42][43] - Non-GAAP tax rate for 2023 is expected to be between 16.5% and 17% [47] Q&A Session Summary Question: Insights on the Horizon transaction and obesity treatment - Management discussed the differentiated profile of AMG 133 for obesity and the ongoing Phase 2 trial, expressing confidence in its potential [50][51] Question: Clarification on interest expense and revenue guidance - Management confirmed that the $700 million run rate includes all expenses and highlighted strong performance in the base business contributing to revenue guidance [55][60] Question: Outlook for Tepezza and other Horizon assets - Management provided positive indicators for Tepezza's growth in the U.S. and international markets, emphasizing favorable payer policies and increasing prescriber numbers [63][67] Question: Investments in AI technology - Management expressed excitement about the integration of AI in drug discovery and development, anticipating significant qualitative changes in the process [71][74]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☑ EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or ...

Amgen Inc. (NASDAQ:AMGN) Amgen Conference Call Following European Society for Medical Oncology Congress 2023 October 24, 2023 8:00 AM ET Company Participants David Reese – Executive Vice President-Research and Development Taofeek Owonikoko – Division Chief-Division of Hematology-Oncology, UPMC Hillman Cancer Ctr. Tarlatamab Jean-Charles Soria – Senior Vice President-Research and Development Kevin Kelly – Chair, Department of Medical Oncology, Sidney Kimmel Medical College Conference Call Participants Salvee ...

Hematology/Oncology Update ESMO 2023 SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa-Kirin Co., Ltd.), the performance of Otezla ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_f40de14a20e804d3a6af5c7e984f91c3.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_4f034bd9fec7da888ff907c6390a7800.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_a86cfbdc1df4a04c795f2267227eb86a.html ...

Q2 ’23 Earnings Call Safe Harbor Statement Thispresentationcontainsforward-lookingstatementsthatarebasedonthecurrentexpectationsandbeliefsofAmgen. Allstatements,otherthanstatementsofhistoricalfact,arestatementsthatcouldbedeemedforward-looking statements,includinganystatementsontheoutcome,benefitsandsynergiesofcollaborations,orpotentialcollaborations,withanyothercompany(includingBeiGene,Ltd.orKyowa-KirinCo.,Ltd.),theperformanceofOtezla®(apremilast) (includinganticipatedOtezlasalesgrowthandthetimingofnon-GAAP ...

Amgen Inc. (NASDAQ:AMGN) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Arvind Sood – Vice President of Investor Relations Bob Bradway – Chairman and Chief Executive Officer Murdo Gordon – Executive Vice President, Global Commercial Operations Dave Reese – Executive Vice President, Research and Development Peter Griffith – Chief Financial Officer Conference Call Participants Mohit Bansal – Wells Fargo Michael Yee – Jefferies Salveen Richter – Goldman Sachs Jay Olson – Oppenh ...